|
TRMT5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.22901688826005E-13 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.18411963462495E-13 |
| Normal-vs-Stage2 |
1.2701999999587E-06 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62458935193399E-12 |
| Stage1-vs-Stage2 |
2.008500E-02 |
| Stage1-vs-Stage3 |
2.977400E-01 |
| Stage1-vs-Stage4 |
3.371700E-04 |
| Stage2-vs-Stage3 |
9.096900E-03 |
| Stage2-vs-Stage4 |
7.65550000000337E-05 |
| Stage3-vs-Stage4 |
2.366500E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.67144076357317E-12 |
| Normal-vs-AfricanAmerican |
4.16410000037004E-07 |
| Normal-vs-Asian |
3.66460195522222E-11 |
| Caucasian-vs-AfricanAmerican |
5.944400E-01 |
| Caucasian-vs-Asian |
2.846600E-01 |
| AfricanAmerican-vs-Asian |
9.023800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.80766512869468E-12 |
| Male-vs-Female |
6.861800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.85662596408065E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.64146474190829E-12 |
| Normal-vs-Age(81-100Yrs) |
4.417300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.385200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.194800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.588400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.000400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.878000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.962200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.082000E-03 |
| Classical-VS-Follicular |
1.319610E-01 |
| Classical-VS-Other |
5.704400E-01 |
| Classical-VS-Normal |
4.03954647509863E-12 |
| Tall-VS-Follicular |
1.021350E-04 |
| Tall-VS-Other |
3.087600E-01 |
| Tall-VS-Normal |
2.66453525910038E-15 |
| Follicular-VS-Other |
3.540600E-01 |
| Follicular-VS-Normal |
1.81080039851622E-10 |
| Other-VS-Normal |
5.626700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.55111512312578E-16 |
| Normal-vs-N1 |
1.11022302462516E-16 |
| N0-vs-N1 |
1.371300E-04 |
|
|
